Hi @mcsulli There are numerous reports released, including from PubMed, regarding the studies on Besremi to treat Myeloproliferative disorders, such as PV and ET, where the JAK2 mutated gene is involved.

Besremi was initially approved for PV in November 2021 citing the outcome of the study which showed patients treated with ropeginterferon alfa-2b (Besremi) showed durable hematologic responses and reductions in JAK2 V617F allele burden compared with those receiving hydroxyurea or best available therapy. The trials demonstrated a reduction in JAK2 allele burden, a surrogate marker associated with lower risk of thrombosis and disease progression over time. In PV the mutated JAK2 gene is responsible for the over production of red blood cells.

Similar results were shown for the reduction in the JAK2 burden for patients with ET (essential thrombocythemia where mutation was causing the production of too many platelets.

This article from Medfinder summed up the information in an easy manner:
>How does Besremi work
https://www.medfinder.com/blog/how-does-besremi-work-mechanism-of-action-explained
Links to articles on the reduction in allele burden of the JAK2 mutation:
>Targeted Oncology:
https://www.targetedonc.com/view/ropeginterferon-alfa-shows-disease-modifying-potential-in-polycythemia-vera
>PubMed “ Long-term outcomes of polycythemia vera patients treated with Interferon alfa not only restores normal blood cell counts in patients with polycythemia vera (PV) but can diminish the mutant JAK2 V617F allele burden.”

From this article in PubMed
https://pmc.ncbi.nlm.nih.gov/articles/PMC9061291/
I’m only tossing these articles out here for information. This are options to discuss with your doctor. This may not be an option for everyone or even warranted if HU is doing the job.